REMARKS

In the Office Communication mailed September 7, 2007, the Examiner has required that applicants elect a group of claims.

Accordingly, applicants provisionally elect, with traverse, Group I.

Applicants note that upon a finding that the elected species is allowable, the Examiner is required to search additional species. Further, Applicants note that non-elected method claims are subject to rejoinder upon allowance of compound claims.

Applicants do not contest the Examiner's evaluation that the Groups are patentably distinct. However, applicants traverse the restriction because the search of more than one Group would not place an undue burden on the Examiner.

Regarding applicants' amendments to the claims, the claims have been amended to use standard U.S. Markush language, that is, using either "the group consisting of" or "or" recitations. These amendments reflect that the scope of the claims include the Markush species, either individually or in combination. Furthermore, applicants have deleted the "pharmaceutically acceptable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios " recitation in the claims depending directly or indirectly from claim 1 and claim 38 (except for claim 9, due to the wording of this claim). This amendment has been made because the deleted language is recited in claim 1 and therefore is incorporated into each of the claims depending directly or indirectly from claims 1 and 38. Furthermore, applicants have clarified antecedent basis, for example, by deleting "the" in certain of the claims.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact the undersigned at the telephone number listed below to expedite prosecution.

U.S. Patent Application No.: 10/579,222 Attorney Docket No.: 978725.9/MPG-P0008

The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account Number 50-3380, referencing Attorney Docket No. 978725.9.

Respectfully submitted,

BAKER & DANIELS.

Ву

Ronald J. Kamis, Reg. No. 41,104

Baker & Daniels LLP

805 15th Street, N.W., Suite 700

Washington, D.C. 20005 Telephone: (202) 312-7029

Facsimile: (202) 312-7441